Navigation Links
Isolagen Receives Bridge Financing to Allow it to Seek Debtor-in-Possession Financing in Connection With a Possible Filing Under Chapter 11 of the United States Bankruptcy Code
Date:5/6/2009

if at all. If the Company is unable to secure sufficient debtor-in-possession financing, it will likely cease operations and may file a petition for protection from creditors under Chapter 7 of the Bankruptcy Code.

The Company was advised today that due to the foregoing disclosure effective immediately the NYSE Amex LLC, formerly known as the American Stock Exchange ("NYSE Amex"), has halted trading in the Company's common stock. The Company has been further advised that it will receive a notice from the NYSE Amex that the exchange intends to delist the Company's common stock from listing on the NYSE Amex, which delisting will occur approximately seven days from the receipt of such notification if the Company determines not to appeal such decision. If the Company's common stock is delisted from the NYSE Amex, the Company intends to apply to have its common stock quoted on the OTC Bulletin Board as soon as practicable after the delisting. If the Company's common stock is delisted from the NYSE Amex, the Company does not anticipate that the trading of the Company's common stock will recommence prior to the exchange's delisting of the common stock and its quotation on the OTC Bulletin Board.

About Isolagen, Inc.

Isolagen(TM), Inc. (NYSE Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For
'/>"/>

SOURCE Isolagen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study
2. Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex
3. Isolagen, Inc. Sells Switzerland Facility
4. Isolagen, Inc. Promotes Todd Greenspan to Chief Financial Officer (CFO)
5. Isolagen, Inc. Receives Notification Letter from American Stock Exchange
6. Isolagen Inc. Promotes Declan Daly to Chief Executive Officer (CEO)
7. Isolagen Inc. to Present at the 26th Annual JPMorgan Healthcare Conference
8. Isolagen Modifies Ongoing Clinical Program for Acne Scars
9. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
10. Isolagen, Inc. Postpones Annual Meeting
11. Bertram Receives Organizational Innovation Award at AONE Conference -- Award Sponsor B. E. Smith Also Announces Funding for Three Seed Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional ... from Administrative assistant to Executive Assistant to CEO Mitch Gould for Nutritional Products ... focused on your goals. Kathleen graduated from Florida State University with a ...
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at Estrella ... Colleges , will be hosting a Job Expo to provide a professional, open venue ... Expo has expanded to much more than just a typical job and career fair. ...
(Date:8/29/2015)... ... August 29, 2015 , ... "I have been ... Place, N.Y. "I specialize in manual therapy, and my invention will provide headache ... used for additional muscle dysfunction throughout the body." , They developed THE RELIEVER ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder and President of ... increase acceptance of the chiropractic field in the military. All too often VA hospitals ... Chiropractic was made available to the VA program over a decade ago, the reality ...
(Date:8/29/2015)... CA (PRWEB) , ... August 29, 2015 , ... ProDrop ... X . Each preset contains 15 seconds of unique footage that users can shrink ... rise, fall, zoom, attract and more. Users can customize color, brightness, scale, speed, range, ...
Breaking Medicine News(10 mins):Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2
... the first time, results on the impact of gaming devices ... at the EULAR 2011 Annual Congress. Data comparing two schools ... of pain following long term use of gaming devices and ... joint health. , The study, involving 257 students, highlights that ...
... , WEDNESDAY, May 25 (HealthDay News) --,The ability of ... level of commitment in their romantic relationships can be traced ... finds. Researchers asked 78 people aged 20 or 21 ... their relationship. The researchers already had data on the ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, ... doctors a community has, especially ones who are actually ... are, a new Dartmouth study suggests. Those ... death rate among local elders, the researchers found. ...
... Goodwin HealthDay Reporter , TUESDAY, May 24 (HealthDay ... pitched sounds when underwater than they can while on terra ... with their bones rather than through the normal pathways of ... humans hear above or below water differs; that difference means ...
... Clinical trials for a new bladder cancer therapy show ... the breakthrough using the drug Urocidin follows thirty years ... am optimistic about the results of the trial," says ... at Queen,s University and director of the Queen,s University ...
... News) -- Losing weight may not be required to lower ... Rather, the study found, small dietary changes can make a ... among blacks. For the study, published online May 18 ... researchers put 69 overweight people at risk for diabetes on ...
Cached Medicine News:Health News:Children experience wrist and finger pain when using gaming devices and mobile phones over time 2Health News:Capacity for Commitment May Start in Early Childhood 2Health News:More Primary Care Docs in a Community Equals Healthier Seniors 2Health News:More Primary Care Docs in a Community Equals Healthier Seniors 3Health News:Underwater, Humans Hear Through Their Bones 2Health News:Underwater, Humans Hear Through Their Bones 3Health News:New made-in-Canada therapy for bladder cancer shows promising results 2Health News:Simply Eating Less Fat May Cut Diabetes Risk 2
(Date:8/28/2015)... , Aug. 28, 2015  Delays in ... projects can slow down the decision-making process, resulting ... therefore, absolutely critical for biopharmaceutical companies to develop ... approval process for quicker and more meaningful insights. ... Best Practices, LLC, nearly three-quarters of benchmarked study ...
(Date:8/28/2015)... 2015 Research and ... of the "12th Annual Report and Survey ... to their offering. The 2015 12th ... and Production is the most recent study of ... projected future capacity and production. The report contains ...
(Date:8/28/2015)... 28, 2015 Research ... of the "Investigation Report on China,s Insulin ... Developed by Novo Nordisk, insulin aspart ... important drug for the treatment of diabetes. Compared ... acting insulin analog, starts working fast and reports ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... issued today a shareholders, letter discussing the results of its fiscal ... Dear Imagenetix shareholder - Following ... we commence the new fiscal year, I would like to address ...   Over the past few years our primary strategy ...
... July 12, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ... 1 clinical trial of APD811, an orally bioavailable agonist ... treatment of pulmonary arterial hypertension, or PAH. ... tolerability and pharmacokinetics of 0.03 mg, 0.05 mg, 0.1 ...
Cached Medicine Technology:Imagenetix, Inc. Discusses March 31, 2011 Fiscal Year End Results and Future Focus 2Imagenetix, Inc. Discusses March 31, 2011 Fiscal Year End Results and Future Focus 3Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 4
... Quality Analysis System) developed by Pablo Artal, ... first diagnostic tool for ophthalmology that provides ... system. Never before has an ophthalmologist had ... quality of vision. , ,OQAS works by ...
... -Chagas is an in-vitro diagnostic test ... to Trypanosoma cruzi in human serum/plasma. ... particle-agglutination assay using gelatin particles coated ... coated gelatin particles are agglutinated in ...
Inquire...
Elisa test for qualitative detection of Total antibodies to Trypanosoma Cruzi in human serum or plasma....
Medicine Products: